Pfizer Inc PFE.N slid 3.8% after U.S. health regulators declined to approve the treatment for growth hormone deficiency in children that it developed with partner OPKO Health Inc OPK.O. Shares of OPKO dropped 12.0%. The highly anticipated Fed meeting concludes on Wednesday and the market will pay close attention to how worried the U.S. central bank is over surging inflation and how aggressive they will be in trying to contain it.